Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.40 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16105
Sealed predictions
- CAMTA1 in dopamine neurons, braak+0.06 (p 0.879) → -0.43 (p 0.243)receipt 16112
Swarm cases
receipt 16112: CAMTA1 in dopamine neurons, braak
- power
- full sample -0.21 (p 0.413, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.16 (p 0.526, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.44 (p 0.069, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.11, sign flips 0; without severely affected donors -0.21 (p 0.413, n 18). fragile.
- cell type
- strongest in microglia: -0.62 (p 0.0062, n 18) vs -0.21 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CAMTA1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CAMTA1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 1.4e-4)
Receipts
loading the receipts